Your browser doesn't support javascript.
loading
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher, Fatima; Moodie, Zoe; Cohen, Kristen W; Grunenberg, Nicole; Bekker, Linda-Gail; Allen, Mary; Frahm, Nicole; Yates, Nicole L; Morris, Lynn; Malahleha, Mookho; Mngadi, Kathryn; Daniels, Brodie; Innes, Craig; Saunders, Kevin; Grant, Shannon; Yu, Chenchen; Gilbert, Peter B; Phogat, Sanjay; DiazGranados, Carlos A; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Bentley, Carter; Mkhize, Nonhlanhla N; Pensiero, Michael N; Mehra, Vijay L; Kublin, James G; Corey, Lawrence; Montefiori, David C; Gray, Glenda E; McElrath, M Juliana; Tomaras, Georgia D.
  • Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
  • Allen M; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Yates NL; Departments of Surgery and Immunology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.
  • Morris L; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
  • Malahleha M; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Mngadi K; Setshaba Research Centre, Soshanguve, South Africa.
  • Daniels B; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Innes C; South African Medical Research Council, Durban, South Africa.
  • Saunders K; Aurum Institute, Klerksdorp Research Centre, Klerksdorp, South Africa.
  • Grant S; Departments of Surgery and Immunology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.
  • Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Phogat S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • DiazGranados CA; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
  • Koutsoukos M; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
  • Van Der Meeren O; GSK Vaccines, Rixensart, Belgium.
  • Bentley C; GSK Vaccines, Rixensart, Belgium.
  • Mkhize NN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Pensiero MN; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
  • Mehra VL; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Kublin JG; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Corey L; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Montefiori DC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Gray GE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • McElrath MJ; Departments of Surgery and Immunology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.
  • Tomaras GD; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
PLoS Med ; 17(2): e1003038, 2020 02.
Article en En | MEDLINE | ID: mdl-32092060
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Linfocitos T CD4-Positivos / Infecciones por VIH / Inmunización Secundaria / Vacunas contra el SIDA / Proteínas del Virus de la Inmunodeficiencia Humana / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male País como asunto: Africa Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Linfocitos T CD4-Positivos / Infecciones por VIH / Inmunización Secundaria / Vacunas contra el SIDA / Proteínas del Virus de la Inmunodeficiencia Humana / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male País como asunto: Africa Idioma: En Año: 2020 Tipo del documento: Article